| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 417.122 | 472.431 | 549.034 | 509.102 | 486.486 | 563.258 | 604.446 | 672.497 | 694.939 | 706.115 |
| Total Income - EUR | 417.123 | 472.432 | 549.086 | 514.666 | 487.140 | 563.329 | 604.557 | 673.277 | 695.568 | 706.879 |
| Total Expenses - EUR | 409.677 | 483.779 | 536.749 | 515.719 | 485.872 | 540.413 | 577.365 | 644.605 | 686.202 | 713.252 |
| Gross Profit/Loss - EUR | 7.446 | -11.347 | 12.337 | -1.054 | 1.269 | 22.916 | 27.193 | 28.671 | 9.366 | -6.373 |
| Net Profit/Loss - EUR | 4.071 | -11.889 | 5.528 | -6.259 | -3.680 | 18.184 | 21.810 | 22.588 | 4.945 | -7.470 |
| Employees | 8 | 12 | 15 | 0 | 16 | 15 | 12 | 12 | 12 | 11 |
Check the financial reports for the company - Acg-Co Pharma 2005 Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 343 | 12.692 | 9.230 | 6.268 | 15.191 | 11.203 | 7.654 | 3.641 | 1.496 | 866 |
| Current Assets | 196.647 | 197.440 | 246.839 | 260.167 | 236.175 | 294.672 | 259.851 | 324.788 | 295.333 | 330.587 |
| Inventories | 97.982 | 125.582 | 143.830 | 160.957 | 140.939 | 170.227 | 158.437 | 188.040 | 176.759 | 182.254 |
| Receivables | 90.502 | 27.212 | 77.134 | 77.405 | 65.152 | 86.428 | 60.487 | 100.555 | 111.932 | 129.001 |
| Cash | 8.163 | 44.646 | 25.874 | 21.805 | 30.084 | 38.016 | 40.926 | 36.192 | 6.642 | 19.331 |
| Shareholders Funds | 26.908 | 14.744 | 20.023 | 4.803 | 3.589 | 21.650 | 42.957 | 45.531 | 48.141 | 39.090 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 177.905 | 200.335 | 239.246 | 263.002 | 250.672 | 286.405 | 227.708 | 285.516 | 249.722 | 292.798 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 887 | 426 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Acg-Co Pharma 2005 Srl